risperidone has been researched along with Movement Disorders in 33 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 9.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "This case report documents the response of a young, first-episode, neuroleptic naive male with severe catatonic schizophrenia to the novel antipsychotic, risperidone." | 7.70 | Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia. ( Caudle, C; Kopala, LC, 1998) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 6.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "This study aims to determine the effectiveness of paliperidone extended release (ER) on cognitive function in patients with schizophrenia in comparison with risperidone." | 5.16 | Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. ( Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS, 2012) |
| "Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone." | 5.11 | Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. ( Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004) |
| "The effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial." | 5.10 | Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. ( Green, MF; Harvey, PD; McGurk, SR; Meltzer, HY, 2003) |
| " Risperidone is associated with relatively few motor side effects compared with the traditional antipsychotics, and weight gain is less likely with risperidone than with either clozapine or olanzapine." | 4.80 | Risperidone side effects. ( Conley, RR, 2000) |
| "We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels." | 3.96 | Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation. ( Ayanoğlu, M; Aydin, HI; Korgali, E; Sezer, T; Sönmez, FM, 2020) |
| "To describe a cohort of young users of risperidone and quetiapine in the province of Manitoba (Canada) and assess the risk for movement disorders in the two treatments." | 3.85 | Movement Disorders in Children and Adolescents Receiving Antipsychotic Pharmacotherapy: A Population-Based Study. ( Alessi-Severini, S; Biscontri, RG; Bugden, S; Collins, DM; Jha, S; Katz, LY, 2017) |
| "Antipsychotic drugs have been used in the treatment of schizophrenia and their long-term use can cause movement disorders, such as tardive dyskinesia (TD) in humans mainly typical ones such as haloperidol." | 3.83 | Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics. ( De Freitas, CM; Duarte, MM; Fachinetto, R; Ferrari, MC; Leal, CQ; Peroza, LR; Schaffer, LF, 2016) |
| " In the present study we investigated the influence of two common MDR1 polymorphisms on the improvement of psychopathological symptoms and occurrence of extrapyramidal side effects (EPS) in Slovenian schizophrenia patients acutely treated with risperidone." | 3.76 | MDR1 gene polymorphisms and response to acute risperidone treatment. ( Dolzan, V; Grabnar, I; Kastelic, M; Koprivsek, J; Locatelli, I; Mandelli, L; Plesnicar, BK; Serretti, A, 2010) |
| "This case report documents the response of a young, first-episode, neuroleptic naive male with severe catatonic schizophrenia to the novel antipsychotic, risperidone." | 3.70 | Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia. ( Caudle, C; Kopala, LC, 1998) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 2.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "RLAI and OP show good short- and long-term safety when treating patients with schizophrenia, with uncommon discontinuation due to adverse effects." | 2.46 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. ( Cañas, F; Möller, HJ, 2010) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| "Aripiprazole is a novel, third-generation antipsychotic with comparable efficacy to SGAs, but a more favorable side effect profile." | 1.36 | Aripiprazole as a viable alternative for treating delusions of parasitosis. ( Bhutani, T; Busse, KL; Koo, JY; Ladizinski, B, 2010) |
| "Central pontine and extrapontine myelinolysis (CPEM) are rare conditions usually associated with rapid correction of hyponatremia." | 1.34 | Psychotic disorder in a patient with central and extrapontine myelinolysis. ( Krystal, A; Lim, L, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 18 (54.55) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Ayanoğlu, M | 1 |
| Korgali, E | 1 |
| Sezer, T | 1 |
| Aydin, HI | 1 |
| Sönmez, FM | 1 |
| Stämpfli, D | 1 |
| Weiler, S | 1 |
| Burden, AM | 1 |
| Biscontri, RG | 1 |
| Jha, S | 1 |
| Collins, DM | 1 |
| Bugden, S | 1 |
| Katz, LY | 1 |
| Alessi-Severini, S | 1 |
| Chatterjee, B | 1 |
| Sharan, P | 1 |
| Kruse, JL | 1 |
| Davis, MC | 1 |
| Saddichha, S | 1 |
| Talukdar, D | 1 |
| Gopal, S | 1 |
| Xu, H | 1 |
| Bossie, C | 1 |
| Burón, JA | 1 |
| Fu, DJ | 1 |
| Savitz, A | 1 |
| Nuamah, I | 1 |
| Hough, D | 1 |
| Alblowi, MA | 1 |
| Alosaimi, FD | 1 |
| Peroza, LR | 1 |
| Schaffer, LF | 1 |
| De Freitas, CM | 1 |
| Leal, CQ | 1 |
| Ferrari, MC | 1 |
| Duarte, MM | 1 |
| Fachinetto, R | 1 |
| Thomas Antérion, C | 1 |
| Convers, P | 1 |
| Desmales, S | 1 |
| Borg, C | 1 |
| Laurent, B | 1 |
| Kastelic, M | 1 |
| Koprivsek, J | 1 |
| Plesnicar, BK | 1 |
| Serretti, A | 1 |
| Mandelli, L | 1 |
| Locatelli, I | 1 |
| Grabnar, I | 1 |
| Dolzan, V | 1 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Cañas, F | 1 |
| Möller, HJ | 1 |
| Caroff, SN | 1 |
| Davis, VG | 1 |
| Miller, DD | 1 |
| Davis, SM | 1 |
| Rosenheck, RA | 3 |
| McEvoy, JP | 1 |
| Campbell, EC | 1 |
| Saltz, BL | 1 |
| Riggio, S | 1 |
| Chakos, MH | 1 |
| Swartz, MS | 1 |
| Keefe, RS | 1 |
| Stroup, TS | 1 |
| Lieberman, JA | 1 |
| Suzuki, T | 1 |
| Takeuchi, H | 1 |
| Watanabe, K | 1 |
| Ladizinski, B | 1 |
| Busse, KL | 1 |
| Bhutani, T | 1 |
| Koo, JY | 1 |
| Pringsheim, T | 1 |
| Kovacs, N | 1 |
| Balas, I | 1 |
| Janszky, J | 1 |
| Simon, M | 1 |
| Fekete, S | 1 |
| Komoly, S | 1 |
| Chrisphonte, P | 1 |
| Ostroff, RB | 1 |
| Gadit, A | 1 |
| Kim, SW | 1 |
| Chung, YC | 1 |
| Lee, YH | 1 |
| Lee, JH | 1 |
| Kim, SY | 1 |
| Bae, KY | 1 |
| Kim, JM | 1 |
| Shin, IS | 1 |
| Yoon, JS | 1 |
| Harvey, PD | 1 |
| Green, MF | 1 |
| McGurk, SR | 1 |
| Meltzer, HY | 1 |
| Karakurum, B | 1 |
| Karatas, M | 1 |
| Yildirim, T | 1 |
| Turner, M | 1 |
| Eerdekens, E | 1 |
| Jacko, M | 1 |
| Eerdekens, M | 1 |
| Erickson, CA | 1 |
| Stigler, KA | 1 |
| Posey, DJ | 1 |
| McDougle, CJ | 1 |
| Lim, L | 1 |
| Krystal, A | 1 |
| Evidente, VG | 1 |
| Gwinn-Hardy, K | 1 |
| Caviness, JN | 1 |
| Alder, CH | 1 |
| Glazer, WM | 1 |
| Conley, RR | 1 |
| Masand, PS | 1 |
| Kopala, LC | 1 |
| Caudle, C | 1 |
| Friedlander, R | 1 |
| Lazar, S | 1 |
| Klancnik, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response[NCT03495024] | Phase 4 | 10 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial[NCT00827840] | Phase 4 | 58 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for risperidone and Movement Disorders
| Article | Year |
|---|---|
Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.
Topics: Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Comorbidity; Conduct Disor | 2021 |
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dyslipidem | 2010 |
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Depression; Female; Haloper | 2005 |
Risperidone in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Diabetes Mellitus; Expert Testi | 2005 |
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brain; Clozapine; Dibenzothiazepines; | 2000 |
Risperidone side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Inc | 2000 |
4 trials available for risperidone and Movement Disorders
| Article | Year |
|---|---|
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Depressio | 2012 |
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Topics: Adolescent; Adult; Arousal; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2003 |
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, | 2004 |
23 other studies available for risperidone and Movement Disorders
| Article | Year |
|---|---|
Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation.
Topics: Child; Creatine Kinase; Dopamine Antagonists; Guanidinoacetate N-Methyltransferase; Humans; Language | 2020 |
Movement Disorders in Children and Adolescents Receiving Antipsychotic Pharmacotherapy: A Population-Based Study.
Topics: Adolescent; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cohort Studies; Female; Humans; Mal | 2017 |
Tardive dyskinesia in a pregnant woman with low dose, short-duration risperidone: possible role of estrogen-induced dopaminergic hypersensitivity.
Topics: Adult; Bipolar Disorder; Dopamine Antagonists; Estrogens; Female; Humans; Movement Disorders; Pregna | 2014 |
New-onset extrapyramidal symptoms following oxcarbazepine discontinuation in a child receiving risperidone.
Topics: Antipsychotic Agents; Carbamazepine; Child; Drug Interactions; Drug Therapy, Combination; Humans; Ma | 2014 |
Serpentine tongue syndrome associated with risperidone long-acting injection treatment.
Topics: Antipsychotic Agents; Humans; Male; Middle Aged; Movement Disorders; Risperidone; Syndrome; Tongue | 2014 |
Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 2014 |
Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug.
Topics: Adult; Antipsychotic Agents; Female; Humans; Movement Disorders; Psychotic Disorders; Risperidone; S | 2015 |
Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corpus Striatum; Cytokines; Haloperidol; Male; Move | 2016 |
An odd manifestation of the Capgras syndrome: loss of familiarity even with the sexual partner.
Topics: Aged; Amnesia; Antipsychotic Agents; Atrophy; Brain; Capgras Syndrome; Donepezil; Hallucinations; Hu | 2008 |
MDR1 gene polymorphisms and response to acute risperidone treatment.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Me | 2010 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Movement Disorders; Olanzapine; Psychotic Disorders; | 2010 |
Aripiprazole as a viable alternative for treating delusions of parasitosis.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Mental Disorders; | 2010 |
Missed diagnosis of tardive dystonia in an adolescent girl treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Delayed Diagnosis; Female; Humans; Movement Disorders; Risperidone | 2011 |
Status dystonicus in tardive dystonia successfully treated by bilateral deep brain stimulation.
Topics: Adolescent; Antipsychotic Agents; Clonazepam; Deep Brain Stimulation; Disability Evaluation; Electro | 2011 |
Perphenazine suspension: a new, old treatment, side effects and continuous use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Clinical Trials as Topic; Dru | 2012 |
Risperidone associated tardive dyskinesia--a less common phenomenon.
Topics: Anxiety; Depression; Humans; Male; Middle Aged; Movement Disorders; Risperidone; Serotonin Antagonis | 2011 |
Risperidone as an alternative treatment for paroxysmal kinesigenic dyskinesia.
Topics: Antipsychotic Agents; Brain Neoplasms; Chorea; Complementary Therapies; Female; Hematoma; Humans; Ma | 2003 |
Psychotic disorder in a patient with central and extrapontine myelinolysis.
Topics: Antidepressive Agents, Second-Generation; Antiparkinson Agents; Antipsychotic Agents; Baclofen; Fema | 2007 |
Risperidone is effective in severe hemichorea/hemiballismus.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chorea; Dopamine Antagonists; Female; Humans; Movemen | 1999 |
Side effects of antipsychotics in the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine | 2000 |
Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Humans; Male; Movement Disorders; Psychiatric Status Rating Scales | 1998 |
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; M | 2001 |